Popular Stories
- Arcutis Biotherapeutics (N
- Nexgel: Bringing Innovatio
- Ekso Bionics: Advancing Ra
- Esperion: Revolutionizing
- AMSC: Restructuring the Po
- Harrow Inc: Envisioning a
SAMPLE REPORTS
- Company Summary.pdf
- Daily Market Updates.pdf
- Initiating Coverage.pdf
- Investors' Presentation.pdf
- Portfolio Performance Analysis.pdf
- Pre-Result Analysis.pdf
- Result Review.pdf
- Short Initiating Coverage.pdf

Influenza Tag

  • All
  • Beauty
  • Biotechnology
  • Cannabis
  • Communications
  • Education
  • Energy
  • Entertainment
  • Environment
  • ETFs
  • Finance
  • Fitness
  • Food and Beverage
  • Healthcare
  • Hospitality
  • Insider Trading
  • Investing Ideas
  • Macro
  • Market Insight
  • Miscellaneous
  • Power
  • Real Estate
  • Retail
  • Sectors
  • Security
  • Startups
  • Technologies
  • Trending
  • Uncategorized
Altimmune leveraging novel intranasal technology in the race against coronavirus

Altimmune Inc (NASDAQ: ALT), a clinical stage biotechnology Company developing immunotherapies for unmet medical needs, announced that the Company has completed designing and synthesis of a novel single-dose, intranasal vaccine to protect against COVID-19, developed using its proprietary intranasal vaccine technology. [caption id="attachment_20787" align="aligncenter" width="271"] Image...

05 March, 2020 0 Comments
Paratek withdraws European Marketing Authorization for Nuzyra

Paratek Pharmaceuticals (NASDAQ: PRTK), a commercial-stage biopharmaceutical Company, announced the withdrawal of its submission to the European Medicines Agency (EMA), for the grant of Marketing Authorization Application (MAA) for NUZYRA® (omadacycline). The Company was developing the candidate for two indications namely, acute bacterial skin and...

23 October, 2019 0 Comments
WordPress Video Lightbox Plugin